That helps explain how a total of 33 stocks in the S&P 500 have implied upside of at least 50% over the next 12 months or so, ...

Biogen Inc. closed 51.05% below its 52-week high of $238.00, which the company reached on July 12th.

With a market cap of $17.4 billion, Biogen Inc. (BIIB) is a global biotechnology leader focused on discovering, developing, ...

Leqembi gains European approval after CHMP reversal, despite safety concerns tied to brain swelling and bleeding in Alzheimer ...

The European Commission on Tuesday authorized the use of Eisai and Biogen's drug to treat some patients with mild cognitive impairment in the early stages of Alzheimer's disease, ending a more than ...

Following the nod in the EU, BIIB & Eisai's Leqembi becomes the first therapy to slow the progression of early Alzheimer's ...

Biogen Inc. and Genentech Inc. are heading to trial in June over a significant contract dispute concerning patent royalties ...

The European Commission (EC) has at last granted the amyloid-beta (Aβ) monoclonal antibody Leqembi (lecanemab) Marketing ...

In a report released today, David Amsellem from Piper Sandler reiterated a Hold rating on Biogen (BIIB – Research Report), with a price target ...

Jefferies analyst Michael Yee maintained a Hold rating on Biogen (BIIB – Research Report) today and set a price target of $130.00. The ...

Biogen (BIIB) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Shares in major U.S. and European pharmaceutical companies fell sharply Wednesday, underperforming a broader market downturn, after U.S. President Donald Trump said the country would soon impose “a ...